v3.25.2
Income taxes (Details) - USD ($)
 12 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Operating Loss Carryforwards [Abstract]    
Income/(loss) before income taxes $ (12,767,000) $ (14,685,000)
Effective tax rate 25.06% 12.47%
Operating loss carryforward, percentage deduction limitation on use 80.00%  
Operating loss carryforwards, period of credits 20 years  
Research and Development Expense $ 9,511,000 $ 4,683,000
Net operating loss carryforwards, minimum percentage of ownership change 50.00%  
Net operating loss carryforwards, period of ownership change 3 years  
Accrued interest and penalties $ 0  
Government assistance expense recorded as reduction of research and development expenses 0 $ (55,000)
Orphan drug tax credit [Member]    
Operating Loss Carryforwards [Abstract]    
Net operating loss carryforwards 1,583,000  
Scientific research and experimental development expenditures investment tax credit [Member]    
Operating Loss Carryforwards [Abstract]    
Tax Credit Carryforward, Amount 3,922,000  
Federal [Member]    
Operating Loss Carryforwards [Abstract]    
Net operating loss carryforwards 18,621,000  
State [Member]    
Operating Loss Carryforwards [Abstract]    
Net operating loss carryforwards 18,621,000  
Canadian Federal {Member]    
Operating Loss Carryforwards [Abstract]    
Net operating loss carryforwards 143,346,000  
Research and Development Expense 25,708,000  
Quebec [Member]    
Operating Loss Carryforwards [Abstract]    
Net operating loss carryforwards 141,851,000  
Research and Development Expense $ 27,887,000